<--- Back to Details
First PageDocument Content
Biology / Pharmacology / Boceprevir / Telaprevir / Hepatitis C virus / Ribavirin / Interferon / Peginterferon alfa-2a / Hepatitis C / Protease inhibitors / Antivirals / Medicine
Date: 2013-01-22 12:54:54
Biology
Pharmacology
Boceprevir
Telaprevir
Hepatitis C virus
Ribavirin
Interferon
Peginterferon alfa-2a
Hepatitis C
Protease inhibitors
Antivirals
Medicine

HCV Treatment Pipeline Update | Pipeline Report

Add to Reading List

Source URL: www.hepcassoc.org

Download Document from Source Website

File Size: 346,71 KB

Share Document on Facebook

Similar Documents

PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno

DocID: 1vlwz - View Document

IMPORTANT PLEASE READ PART III: CONSUMER INFORMATION INTRON A® interferon alfa-2b This leaflet is part III of a three-part "Product Monograph"

DocID: 1uNBi - View Document

Evaluation of Interferon-gamma-Producing T Cells

DocID: 1uFKZ - View Document

PRODUCT MONOGRAPH INTRON A® interferon alfa-2b Lyophilized Powder with Diluent: 10 million IU interferon alfa-2b/vial

DocID: 1umTG - View Document

  Data Sheet Recombinant Human Interferon-gamma (rh IFN-) Preclinical Grade - Order No.: µg)

DocID: 1u1rK - View Document